Recent Finacing
Recent Raise
Pharnext develops combination therapies (Pleodrugs) using its Pleotherapy/NEXUS genomic and AI-driven discovery engine to repurpose mini-dose drug combinations for neurological diseases like CMT1A and Alzheimer's, advancing clinical trials.
